Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diphtheria
- Lockjaw
- Pertussis
- Tetanus
- Whooping Cough
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Care Provider, Investigator)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 40 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01529645
- Collaborators
- Not Provided
- Investigators
- Study Chair: Novartis Vaccines Novartis Vaccines Principal Investigator: Geert Leroux-Roels, Prof. Dr. Center for Vaccinology (CEVAC), Ghent University Hospital
Get Well Soon